HeiQ Launches Antiviral Textile Tech

From left, HeiQ CEO Carlo Centonze and Dr. Thierry Pelet, holding first prototype of HeiQ Viroblock NPJO3 treated facemasks.

HeiQ’s new Viroblock NPJ03 is an antiviral and antimicrobial textile treatment proven effective against human coronavirus (229E) in facemask testing. According to a company statement, Viroblock NPJ03 significantly enhances “the antiviral log reduction from 2.90 of untreated face masks to 4.48, over 99.99% reduction of virus infectivity.” The company explains that “a log reduction of 2 is equivalent to 100 times the effectiveness.”

“Virologist Dr. Thierry Pelet of HeiQ’s Scientific Advisory Board brought us a profound depth of knowledge and accelerated our efforts to address the urgent problem of a global pandemic,” says Carlo Centonze, HeiQ Group CEO. “Our goal is to prevent textiles from becoming a host surface for propagating harmful viruses and bacteria, and contribute to reduce the risk and speed of contamination and transmission.”

Chinese protective masks producer Suzhou Bolisi is the lead adopter of HeiQ Viroblock NPJ03. Treated masks will be available on the market as early as this April, according to HeiQ. Additionally, HeiQ reports that American legwear manufacturer Kayser-Roth is planning to add the technology to their new product, Ghluv hands protector, while  Lufeng from China is evaluating the technology on other types of fabric used for garments.

HeiQ Viroblock NPJ03 is a unique combination of vesicle and silver technologies designed to inhibit the growth and persistence of bacteria and viruses. The HeiQ vesicle technology targets lipid-enveloped viruses, such as coronavirus, providing rapid virus deactivation, while the HeiQ silver technology inhibits the replication of both bacteria and viruses. HeiQ Viroblock NPJ03 can be applied to a wide spectrum of textile surfaces including facemasks, air filters, medical gowns, curtains, drapes and more.

Both 229E and Covid-19 are two of seven types of human coronaviruses. Besides testing on human coronavirus (229E), HeiQ Viroblock NPJ03 also demonstrates dramatically improved reduction of virus infectivity against Influenza types H1N1, H5N1, H7N9, and Respiratory Syncytial Virus (RSV).